Related references
Note: Only part of the references are listed.Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
Concetta Sciammarella et al.
FRONTIERS IN ONCOLOGY (2020)
Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells
Mariarosaria Negri et al.
NUTRIENTS (2020)
The roles of exosomes in cancer drug resistance and its therapeutic application
Shiyu Li et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Exosomes in the tumor microenvironment as mediators of cancer therapy resistance
Irene Li et al.
MOLECULAR CANCER (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Exosomes derived from HCC cells with different invasion characteristics mediated EMT through TGF-beta/Smad signaling pathway
Zhen Qu et al.
ONCOTARGETS AND THERAPY (2019)
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit
Donatella Paola Provvisiero et al.
SCIENTIFIC REPORTS (2019)
Mechanisms of acquired tumor drug resistance
Svetlana N. Aleksakhina et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
HCC-derived exosomes elicit HCC progression and recurrence by epithelialmesenchymal transition through MAPK/ ERK signalling pathway
Lu Chen et al.
CELL DEATH & DISEASE (2018)
Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and Exhibit Selective Cytotoxicity in MRP1-overexpressing Cells
Kee W. Tan et al.
DRUG METABOLISM AND DISPOSITION (2018)
Vitamin D-induced vitamin D receptor expression induces tamoxifen sensitivity in MCF-7 stem cells via suppression of Wnt/β-catenin signaling
Wei Zheng et al.
BIOSCIENCE REPORTS (2018)
Calcitriol Reverses Induced Expression of Efflux Proteins and Potentiates Cytotoxic Activity of Gemcitabine in Capan-2 Pancreatic Cancer Cells
Hamed Gilzad-Kohan et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2017)
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study
Claudia Pivonello et al.
ENDOCRINE (2017)
The biology and function of exosomes in cancer
Raghu Kalluri
JOURNAL OF CLINICAL INVESTIGATION (2016)
Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
Zhen Qu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma
Claudia Pivonello et al.
ONCOTARGET (2016)
Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and RNAs
Mian He et al.
CARCINOGENESIS (2015)
Exosomes in cancer: small particle, big player
Xu Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf et al.
NATURE (2015)
Microenvironmental regulation of therapeutic response in cancer
Florian Klemm et al.
TRENDS IN CELL BIOLOGY (2015)
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
Maria Serova et al.
ONCOTARGET (2015)
Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells
Tetsuo Nishi et al.
CANCER LETTERS (2013)
Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma
Qian Zhou et al.
INTERNATIONAL JOURNAL OF HEPATOLOGY (2013)
Epithelial-Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines
Hui Zhao et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
Eduardo Vilar et al.
MOLECULAR CANCER THERAPEUTICS (2011)
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Ryan J. O. Dowling et al.
SCIENCE (2010)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Jerome Tamburini et al.
BLOOD (2008)
Clonogenic assay of cells in vitro
Nicolaas A. P. Franken et al.
NATURE PROTOCOLS (2006)
Share Paper
